This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.

Note: We can assist only if the medicine is unavailable in your country.”

Truqap (capivasertib)

General Description:

Truqap (capivasertib) is a prescription medication approved for the treatment of HR-positive, HER2-negative breast cancer in adults that is locally advanced or metastatic and carries PIK3CA, AKT1, or PTEN alterations. It is administered in combination with fulvestrant.

Truqap received FDA approval in the United States in November 2023.

Getting Truqap (capivasertib) in India

Truqap (capivasertib) has been approved in countries like the U.S. and Europe but is not yet available for commercial sale in India. However, it is accessible through the Named Patient Program (NPP) for eligible patients.

MitoGENE helps Indian patients access Truqap (capivasertib) legally and safely under their doctor’s supervision. We handle the documentation, regulatory approvals, and logistics to ensure compliance with Indian regulations.

If you or your loved one may benefit from Truqap (capivasertib), MitoGENE is here to support your journey to access this treatment.

Disease Indications:Breast Cancer

Manufacturer:AstraZeneca Pharmaceuticals LP

Usage:Oral

Medicine Approved by:

  • Food and Drug Administration (FDA)
  • European Medical Agency (EMA)
  • Pharmaceuticals and Medical Devices Agency (PMDA)

Available Dosage Form& Package

  • 64 tablets of 200 mg

Shipping: Room Temperature Shipping. This medication is shipped using standard delivery methods, ensuring it remains within a controlled room temperature range of 15°C to 25°C throughout transit.

What is Truqap (capivasertib) used for?

Truqap (capivasertib) is a prescription medicine used in combination with fulvestrant to treat adult patients with HR-positive, HER2-negative breast cancer that is locally advanced or metastatic and carries one or more PIK3CA, AKT1, or PTEN gene alterations.

It is indicated for use in patients who have previously received at least one endocrine-based therapy in the metastatic setting, or in those whose cancer recurred within 12 months of completing adjuvant endocrine treatment.

How does Truqap (capivasertib) work?

Truqap is a targeted therapy that works by inhibiting the AKT protein, a key component in the signaling pathway that promotes cancer cell growth and survival—especially in HR-positive, HER2-negative breast cancers with specific genetic alterations. By blocking AKT, capivasertib aims to slow or stop tumor progression.

References

  1. HIGHLIGHTS OF PRESCRIBING INFORMATION, Accessdata.fda.gov, Accessed 15 January 2024.
  2. Stewart, Judith. Truqap (capivasertib) FDA Approval History. Drugs.com, 21 November 2023.
  3. Truqap: Side Effects, How It Works, and More. Breastcancer.org, 21 December 2023.

How to Access Truqap (capivasertib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?

If Truqap (capivasertib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:

    Upload Prescription

    Upload Patient Consent Form

    Patient Consent Form
    Download

    Please download and complete this form, including your signature, and attach it to the request form or email it to info@mitogene.org along with the patient details.